Previcox, the canine NSAID containing firocoxib, now comes in a quarterable tablet formulation — a change that expands the dosing options available to veterinarians treating dogs for pain and inflammation, according to DVM 360.

The word on the label does the practical work here. A quarterable tablet is scored so a clinician — or a trained owner following a written protocol — can break it into precise fractions. That single manufacturing detail changes how a dose gets matched to a patient.

Why tablet divisibility matters at the exam table

NSAID dosing in dogs has always run into a packaging problem. Tablets come in fixed strengths. Dogs come in weights that rarely align with those strengths. When the two do not match, the prescriber has three unappealing choices: round up toward a higher-strength tablet, round down and risk underdosing, or ask an owner to split an unscored tablet and hope the halves come out even.

Unscored tablets split unevenly. A "half" can weigh far more or less than half the dose, and with a narrow-margin drug the error compounds across a multi-week course. Scoring, done at the manufacturing stage, is the industry's structural fix: the groove gives the break a predictable plane.

Quartering goes further than halving. It creates four dose steps from a single tablet strength, which tightens the fit between the labeled dose and the patient in front of you. For small dogs sitting between tablet sizes, and for titration protocols where the plan is to step the dose down as the patient improves, that granularity is the clinical point.

What this changes for prescribers

DVM 360's report frames the development as an expansion of dosing options, and the mechanics support that framing:

• One scored tablet strength can now serve a wider weight range, since quartering yields intermediate doses the fixed strengths did not cover.
• Dose adjustments — up for flare-ups, down for maintenance or tapering — can proceed in smaller increments rather than whole-tablet jumps.
• The change applies to the canine formulation; Previcox's equine presentation is a separate product line with its own dosing logic.

None of this alters the pharmacology. Firocoxib remains a COX-2-preferential NSAID, and the prescribing precautions that attend any canine NSAID — gastrointestinal monitoring, renal screening in appropriate patients, owner counseling on administration — still govern its use. What changes is the delivery arithmetic.

The compliance angle

Dosing precision and compliance travel together. An owner asked to give "one and a quarter tablets" of a scored product faces an easier task than one told to guess at an unscored break. Uneven splits produce uneven plasma levels. Uneven plasma levels produce both missed efficacy and amplified adverse-effect risk, and either one lands back at the clinic as a follow-up call.

A quarterable tablet moves that variable out of the owner's kitchen and into the manufacturer's quality control. That is a modest change on paper. At the barn-hands-and-pill-pockets level, it is the difference between a protocol that survives contact with a real household and one that quietly degrades.

What to watch next

DVM 360's report centers on the canine dosing expansion itself; specifics on tablet strengths, pricing, and the full roll-out schedule were not part of the announcement as covered. Veterinarians who dispense firocoxib should watch for the quarterable presentation to reach distributors and for updated labeling that documents the scored dosing increments — the label text is what converts a manufacturing feature into a defensible prescribing instruction.